Inclusion Criteria:

- Radiographic or histologic diagnosis of hepatocellular carcinoma (HCC).

- Maximum of 3 HCC lesions within the liver.

- No evidence of lymphadenopathy or metastatic disease per either CT or PET.

- Prior transarterial chemo-embolization (TACE) at least 28 days prior to initiation of
protocol therapy.

- Evidence of either progressive disease or stable disease following TACE.

- Child Pugh Class A (score 5-6) or B (score 7).

- ECOG Performance Status ≤1 (or Karnofsky ≥70%).

- Normal organ and marrow function (platelets >60,000/mc; hemoglobin ≥8.5 g/dL; INR
≤2.3; albumin ≥2.8 g/dL; total bilirubin ≤3 mg/dL; AST/ALT <5x upper limit of normal;
creatinine ≤1.5x upper limit of normal).

- Negative human immunodeficiency virus serology.

- Negative pregnancy test for women of child bearing age.

- Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

- Less than 800 cc of normal liver.

- Child Pugh Class B (score 8-9) or C (score 10-15).

- Acute/active hepatitis B infection.

- Prior systemic chemotherapy or abdominal radiation therapy.

- Portal venous (main, primary right, or primary left trunks) or inferior vena cava
thrombosis.

- Prior malignancy within 5 years of enrollment except for non-melanoma skin cancer.

- Prior history of myocardial infarction, cerebrovascular accident, or esophageal
variceal bleed in the last 6 months.

- Pre-existing heart failure with either a clinical classification of New York Heart
Association Class III or IV or cardiac ejection fraction of <45%.

- Systolic blood pressure > 160 mmHg or diastolic pressure > 100 mmHg despite optimal
medical management.

- Pulmonary hemorrhage or other serious bleeding event (grade 2+) within 4 weeks
initiation of protocol therapy.

- Prior history of scleroderma or active systemic lupus erythematosus.